Erlotinib intermediates manufacturer
Niraparib is a selective inhibitor of PARP1/PARP2 (The poly(ADP-ribose) polymerase) with great activity in cancer cells with mutant BRCA-1 and BRCA-2.
Niraparib has been recently approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death
| Product Name | Niraparib |
| Synonyms | Niraparib(MK4827) free base;2-[4-(3S)piperidin-3-ylphenyl]-2H-indazol-7-carboxamide;EOS-60867;(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827,(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxaMide;Niraparib;1038915-60-4;2-[4-((3S)-3-Piperidinyl)phenyl]-2H-indazole-7-carboxamide |
| CAS | 1038915-60-4 |
| MF | C19H20N4O |
| MW | 320.3883 |
| EINECS | N/A |
| Product Categories | -;API;Anti-cancer&immunity |
| Mol File | 1038915-60-4.mol |
| density | 1.34 |
